COMPANY PROFILE

Sequenta

Explore full profile

Biotech company developing immune-driven clinical products for personalized disease diagnosis and treatment

Oyster Point, United StatesFounded 2008Biotech & Life Sciences

Valuation $100–250M Last recorded · 2013

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Sequenta

Sequenta is a commercial-stage biotech company focused on harnessing the adaptive immune system to transform the diagnosis and treatment of diseases. The company operates in the life sciences research, clinical diagnostics, and drug discovery markets. Sequenta's proprietary immune medicine platform decodes the genetics of the adaptive immune system with unprecedented scale, precision, and speed, enabling the development of personalized clinical products. The company serves healthcare providers, research institutions, and pharmaceutical companies. Sequenta generates revenue through the commercialization of its diagnostic and therapeutic products, as well as partnerships with industry leaders.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2008
Headquarters: Oyster Point, United States
Employees: 1
Open positions: None listed
Dealroom signal: 60.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2c
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Jan 2015	$0	—	Adaptive Biotechnologies	—
EARLY VC✓Equity / VC	Oct 2014	$0	—	Celgene	—

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Sequenta website traffic

Latest recorded traffic for Sequenta is 290 monthly website visits.

Latest monthly visits290

Monthly website visitsApr 2016–Jun 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
VBVero BiotechAn emerging biotechnology company focused on the design, development, and commercialization of next generation inhaled nitric oxide (NO) delivery systems to address unmet medical needs of patients with cardiopulmonary conditions	Atlanta, United States	Operational	223	$185M	$500M
C2C2CareDesigns therapeutic solutions based on virtual reality in order to immerse patient in an environment that creates a certain stress	Sanary-sur-Mer, France	Operational
RGRevenio GroupEffective and easy-to-use health tech devices for the detection of diseases of significance to public health	Vantaa, Finland	Operational
SBSwaLife BiotechUsing plant-derived compounds, we are reinventing the formulation of sun care products to enhance consumers’ beauty and health	Cork, Ireland	Operational
BTBioSig TechnologiesBioSig Technologies \| Improving the Quality of Cardiac Recordings	Westport, United States	Operational
CVColibri Heart ValveBiotech & Life Sciences	Broomfield, United States	Operational
NENexImmuneBiopharmaceutical company developing novel immuno-therapeutics based on the proprietary artificial immune technology	Gaithersburg, United States	Operational
AUAutoMedxAutoMedx \| Simplifying Pre-hospital Ventialtion \| SAVe	Flower Mound, United States	Operational